Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101 AM1) (DANCHEONG)
This study has been completed.
Study NCT01050543 Information provided by Merck Sharp & Dohme Corp.
First Received on January 14, 2010. Last Updated on June 5, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Interventions listed in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers